HomeHDP1 • FRA
add
Arrowhead Pharmaceuticals Inc
Nakaraang pagsara
€13.56
Sakop ng araw
€13.16 - €13.16
Sakop ng taon
€8.85 - €26.84
Market cap
2.12B USD
Average na Volume
27.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
(USD) | Mar 2025info | Y/Y na pagbabago |
---|---|---|
Kita | 542.71M | — |
Gastos sa pagpapatakbo | 161.51M | 27.99% |
Net na kita | 370.44M | 395.65% |
Net profit margin | 68.26 | — |
Kita sa bawat share | 2.75 | 369.61% |
EBITDA | 386.44M | 417.62% |
Aktuwal na % ng binabayarang buwis | 0.47% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
(USD) | Mar 2025info | Y/Y na pagbabago |
---|---|---|
Cash at mga panandaliang investment | 185.71M | -64.35% |
Kabuuang asset | 1.57B | 64.74% |
Kabuuang sagutin | 889.27M | 93.43% |
Kabuuang equity | 684.22M | — |
Natitirang share | 138.06M | — |
Presyo para makapag-book | 2.74 | — |
Return on assets | 73.67% | — |
Return on capital | 85.14% | — |
Cash Flow
Net change in cash
(USD) | Mar 2025info | Y/Y na pagbabago |
---|---|---|
Net na kita | 370.44M | 395.65% |
Cash mula sa mga operasyon | — | — |
Cash mula sa pag-invest | — | — |
Cash mula sa financing | — | — |
Net change in cash | — | — |
Malayang cash flow | — | — |
Tungkol
Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. Wikipedia
Itinatag
Ene 1, 2004
Headquarters
Website
Mga Empleyado
609